Giovanni Caforio, Bristol Myers Squibb CEO (Nicolas Messyasz/Sipa via AP Images)
FDA approvals, Revlimid LOE and Opdivo's label expansion headline Bristol Myers' start to 2022
The Q1 numbers are in from Bristol Myers Squibb, setting the tone for the year as the pharma giant lines up some key new drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
